11.81 USD
▲+1.21+5.26%
盘后 11.25 +0.27%
2026-08-03
市值
$2.32B
市盈率
—
EPS
-0.23
股息率
—
52 周区间
1.39 – 15.88
成交量
5.09M
Beta
2.42
目标价
27.50
52W 低 1.3952W 高 15.88
价格走势
公司简介
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembroli...